Hydroxychloroquinesulfaat Accord (Hydroxychloroquine Sulfate)

Hydroxychloroquine accumulates inside lysosomes, raising their pH and inhibiting enzymes involved in autophagy and antigen presentation. This disrupts the life cycle of malaria parasites and dampens immune activation by modulating Toll‑like receptor signaling, thereby reducing inflammatory cytokine production in autoimmune diseases.

The exact dose of Hydroxychloroquinesulfaat Accord is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and any concomitant therapies. Dosage regimens are not standardized in public literature and must follow the prescriber’s written order.

Safety data for hydroxychloroquine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit outweighs the possible risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Hydroxychloroquine offers a dual benefit of antimalarial activity and immunomodulation, making it useful for both infectious and autoimmune conditions. Compared with chloroquine, it has a better safety profile and longer half‑life. Relative to biologic DMARDs, it is administered orally, is less costly, but may be less potent for severe disease, requiring careful patient selection.

Hydroxychloroquinesulfaat Accord should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

The medication is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed. Adherence to the prescribed schedule is essential for optimal therapeutic effect.

Serious adverse events include retinal toxicity, which can lead to irreversible vision loss, and cardiotoxicity such as arrhythmias or conduction disturbances. Patients should report any changes in vision, heart palpitations, or unexplained dizziness promptly, and regular ophthalmologic and cardiac monitoring may be recommended.

Hydroxychloroquinesulfaat Accord is contraindicated in individuals with known hypersensitivity to hydroxychloroquine or related compounds. Patients with G6PD deficiency should avoid use due to the risk of hemolysis, and those with pre‑existing retinal disease or significant cardiac conduction abnormalities should be evaluated carefully before treatment.